Side-line actions. side effects

Side-line actions: Tablets with the immediate liberation the side effects, connected with the curtailment of treatment by 19% of patients (537/2897) with the depression, obtained Venlafaxine, with conducting of studies of phase 2 and phase 3 ended treatment in connection with the appearance of side effects. Most general effects (?1%), which were been the reason for the curtailment of therapy and those considering as the caused by method medicines (i.e. observed approximately 2 or more times more frequent with the method of Venlafaxine in the comparison with the placebo), they were following (in the brackets it was indicated percentage in the group of placebo): sleepiness 3% (1%), insomnia 3% (1%), vertigo 3% (1%), headache 3% (1%), anxiety 2% (1%), nervousness 2% (1%), asthenia 2% (1%); dryness in mouth 2% (1%), nausea 6% (1%), the disturbance of ejaculation 3% (1%), sweating 2% (1%). The side effects, which were being observed in the controlled tests by the most frequent side effects, connected with the method of venlafaksina of the hydrochloride (frequency of occurrence 5% and more), not equivalent in the frequency of occurrence in the group of placebo, i.e., with the method venlafaksina of hydrochloride were observed at least 2 times more frequently than in the group of the placebo (see Table 1), there were asthenia, sweating, nausea, bolt, anorexia, vomiting, sleepiness, dryness in the mouth, vertigo, nervousness, anxiety, tremor, carelessness of sight, disturbance of eyakulyatsii/orgazma and impotence in men. The side effects, which were being observed with a frequency of?1% in patients, treated of Venlafaxine by hydrochloride (tabl.y). Table 1 presents the side effects, noted in patients, who obtained Venlafaxine hydrochloride in the form of tablets at the doses of 75-375 mg/day with conducting of short term tests (4 and 8- weekly). These effects were observed with a frequency of?1% and exceeded in the frequency of placebo. Table shows the percentage of the patients in each group, in whom was noted at least one case of separate side effect within the period of treatment.